IL163812A0 - Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein - Google Patents

Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein

Info

Publication number
IL163812A0
IL163812A0 IL16381203A IL16381203A IL163812A0 IL 163812 A0 IL163812 A0 IL 163812A0 IL 16381203 A IL16381203 A IL 16381203A IL 16381203 A IL16381203 A IL 16381203A IL 163812 A0 IL163812 A0 IL 163812A0
Authority
IL
Israel
Prior art keywords
inducing
immune response
cleavage site
response against
precursor protein
Prior art date
Application number
IL16381203A
Other languages
English (en)
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of IL163812A0 publication Critical patent/IL163812A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL16381203A 2002-03-05 2003-03-04 Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein IL163812A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36134402P 2002-03-05 2002-03-05
PCT/US2003/006388 WO2003076455A2 (en) 2002-03-05 2003-03-04 Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein

Publications (1)

Publication Number Publication Date
IL163812A0 true IL163812A0 (en) 2005-12-18

Family

ID=27805031

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16381203A IL163812A0 (en) 2002-03-05 2003-03-04 Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
IL163812A IL163812A (en) 2002-03-05 2004-08-30 Immunizing composition, antigenic product and isolated antigenic peptide for inducing an immune response against beta-secretase cleavage site of amyloid the precursor protein
IL212752A IL212752A (en) 2002-03-05 2011-05-08 Molecule Targeted Against Fission Site by ß - Pre-amyloid Protein Secretion and Its Uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL163812A IL163812A (en) 2002-03-05 2004-08-30 Immunizing composition, antigenic product and isolated antigenic peptide for inducing an immune response against beta-secretase cleavage site of amyloid the precursor protein
IL212752A IL212752A (en) 2002-03-05 2011-05-08 Molecule Targeted Against Fission Site by ß - Pre-amyloid Protein Secretion and Its Uses

Country Status (8)

Country Link
US (3) US7494655B2 (ja)
EP (2) EP2292247A3 (ja)
JP (3) JP2005532276A (ja)
AU (1) AU2003225636A1 (ja)
CA (1) CA2477675C (ja)
ES (1) ES2392247T3 (ja)
IL (3) IL163812A0 (ja)
WO (1) WO2003076455A2 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1398019A1 (de) 2002-09-13 2004-03-17 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Dermal Epidermal Junctions
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
US20080199879A1 (en) * 2004-10-28 2008-08-21 Sanko Junyaku Co., Ltd. Method of Assaying Alzheimer's Disease and Diagnostic Reagent
PL1937284T3 (pl) 2005-10-18 2016-05-31 Starpharma Pty Ltd System podawania kompozycji bakteriobójczego dendymeru
PT1940916T (pt) 2005-10-25 2017-03-20 Starpharma Pty Ltd Composto macromolecular tendo estequiometria controlada
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
CA2636599C (en) 2006-01-20 2014-07-15 Starpharma Pty Limited Modified macromolecule
AU2007229268B2 (en) 2006-03-22 2013-01-10 Starpharma Pty Limited Contraceptive composition
AU2007275258A1 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
DK2052011T3 (da) 2006-08-11 2020-12-07 Starpharma Pty Ltd Målrettet polylysin-dendrimer-terapeutisk stof
EP2091959A4 (en) * 2006-11-28 2010-05-05 Alzhyme Pty Ltd IMPROVED PEPTIDE COMPOSITION
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009041501A1 (ja) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. ヘルペスウイルスの潜伏感染に関与する因子及びその利用
GB0720912D0 (en) * 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP
KR101397554B1 (ko) * 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
US8921523B2 (en) 2007-12-11 2014-12-30 Glaxo Group Limited Humanized anti-beta-amyloid antibodies
WO2009124119A2 (en) * 2008-04-01 2009-10-08 The Trustes of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
WO2009155538A1 (en) * 2008-06-20 2009-12-23 Merck & Co., Inc. Compositions and methods of depleting amyloid-beta peptides from cerebrospinal fluid to treat alzheimer's disease
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
RU2011125971A (ru) * 2008-11-24 2012-12-27 Рамот Эт Тель-Авив Юниверсити Лтд. Способ лечения болезни паркинсона
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
US8617549B2 (en) 2009-09-11 2013-12-31 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Bispecific nanobodies as a therapeutic for alzheimer's disease
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3163301B1 (en) * 2014-06-27 2019-08-07 Japan Tobacco, Inc. Method for treating, or preventing mood disorder
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN106349334A (zh) * 2015-07-15 2017-01-25 韩震 一种多肽化合物及其制备方法与应用
JP6641387B2 (ja) 2015-12-28 2020-02-05 日本たばこ産業株式会社 融合タンパク質及びその利用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376861A (en) 1976-06-23 1983-03-15 The Dow Chemical Company Method for preparing 2-alkenyl-2-oxazolines
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4600535A (en) 1982-02-12 1986-07-15 The Dow Chemical Company Cyclic peptides
US4517122A (en) 1982-02-12 1985-05-14 The Dow Chemical Company Cyclic peptides
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4515920A (en) 1984-04-30 1985-05-07 The Rockefeller University Synthesis of peptides and proteins
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4599400A (en) 1984-12-18 1986-07-08 The Dow Chemical Company Star/comb-branched polyamide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
DE69133372T2 (de) * 1990-06-15 2005-02-24 Scios Inc., Sunnyvale Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
WO1996040885A2 (en) 1995-06-07 1996-12-19 Athena Neurosciences, Inc. β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
WO1998021589A1 (en) 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
WO2000047618A2 (en) 1999-02-10 2000-08-17 Elan Pharmaceuticals, Inc. HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
WO2001014579A2 (en) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
CA2349434A1 (en) * 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
AU2001229592A1 (en) * 2000-01-21 2001-07-31 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
DE60217107T2 (de) * 2001-06-20 2007-08-23 Ramot At Tel Aviv University Ltd. Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
US20070134247A9 (en) * 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
GB0720912D0 (en) * 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP

Also Published As

Publication number Publication date
US20060034855A1 (en) 2006-02-16
IL212752A0 (en) 2011-07-31
IL212752A (en) 2014-01-30
EP1480666B1 (en) 2012-06-13
CA2477675C (en) 2013-05-21
JP5717210B2 (ja) 2015-05-13
WO2003076455A3 (en) 2004-04-08
US20110070249A1 (en) 2011-03-24
EP2292247A3 (en) 2011-10-05
AU2003225636A1 (en) 2003-09-22
US7494655B2 (en) 2009-02-24
JP2013181034A (ja) 2013-09-12
EP1480666A4 (en) 2006-06-07
JP2010248197A (ja) 2010-11-04
AU2003225636A8 (en) 2003-09-22
CA2477675A1 (en) 2003-09-18
IL163812A (en) 2011-06-30
EP2292247A2 (en) 2011-03-09
US7854931B2 (en) 2010-12-21
ES2392247T3 (es) 2012-12-07
WO2003076455A2 (en) 2003-09-18
EP1480666A2 (en) 2004-12-01
JP2005532276A (ja) 2005-10-27
US20070172484A1 (en) 2007-07-26
US8613928B2 (en) 2013-12-24

Similar Documents

Publication Publication Date Title
IL163812A0 (en) Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
EP1583145A4 (en) PROCESS FOR PRODUCING SOI WAFER AND SOI WAFER
EP1575480A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
EP1578367A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1572116A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
IL158831A0 (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
IL174938A0 (en) Ceramic armour and method of construction
HK1076047A1 (en) Method for screening parasite preparations for efficiency in prevention and control of diseases
HK1077836A1 (en) Method of purifying protein
DE60305691D1 (de) Gusseisernes inneres Glied und Herstrellungsverfahren dafür
IL169648A0 (en) Novel structures and method of preparation
EP1489174A4 (en) METHOD FOR MODIFYING THE PROPERTIES OF A PROTEIN
EP1560593A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
AU2003247905A1 (en) Libido stimulating device and method of using
EP1494678A4 (en) hormone therapy PROCEDURE
IL175657A0 (en) Derivatives of dihydronepetalactone and method for preparation
AU2003213718A8 (en) Method of producing antigens
EP1578373A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
EP1491091A4 (en) MEANS OF PROTECTION AGAINST INSECTS AND METHODS OF PROTECTION AGAINST INSECTS
EP1562587A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE IMMUNE SYSTEM
GB0504677D0 (en) Method of creating antigens using emus
GB0319174D0 (en) Apparatus and method for the selective assembly of protein
AU2003230004A8 (en) Methods of therapy for inducing tolerance
GB0203518D0 (en) Wager administration system and method of operation thereof
EP1452597A4 (en) PROTEIN ACTIVATION METHOD